The effect of biological heterogeneity on R-CHOP treatment outcome in diffuse large B-cell lymphoma across five international regions
- 10 October 2016
- journal article
- research article
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 58 (5), 1-6
- https://doi.org/10.1080/10428194.2016.1231308
Abstract
Addressing the global burden of cancer, understanding its diverse biology, and promoting appropriate prevention and treatment strategies around the world has become a priority for the United Nations and International Atomic Energy Agency (IAEA), the WHO, and International Agency for Research on Cancer (IARC). The IAEA sponsored an international prospective cohort study to better understand biology, treatment response, and outcomes of diffuse large B-cell lymphoma (DLBCL) in low and middle-income countries across five UN-defined geographical regions. We report an analysis of biological variation in DLBCL across seven ethnic and environmentally diverse populations. In this cohort of 136 patients treated to a common protocol, we demonstrate significant biological differences between countries, characterized by a validated prognostic gene expression score (p < .0001), but International Prognostic Index (IPI)-adjusted survivals in all participating countries were similar. We conclude that DLBCL treatment outcomes in these populations can be benchmarked to international standards, despite biological heterogeneity.This publication has 15 references indexed in Scilit:
- Prospective International Cohort Study Demonstrates Inability of Interim PET to Predict Treatment Failure in Diffuse Large B-Cell LymphomaJournal of Nuclear Medicine, 2014
- Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With ImmunochemotherapyJournal of Clinical Oncology, 2014
- Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cyclesLancet, 2013
- An appeal to world leaders: stop cancer nowThe Lancet, 2013
- Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOPBlood, 2008
- The Role of Environmental Factors in the Etiology of LymphomaCancer Investigation, 2008
- The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphomaBlood, 2007
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- Report of an International Network of Cancer Treatment and Research workshop on non-Hodgkin's lymphoma in developing countriesBlood Cells, Molecules, and Diseases, 2004
- Prediction of Survival in Diffuse Large-B-Cell Lymphoma Based on the Expression of Six GenesThe New England Journal of Medicine, 2004